Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
NCT04795141 · Inmagene LLC · PHASE2 · terminated · last registry update 2023-07-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The sponsor's development strategy is adjusted.” | – | Registry record, Inmagene LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL17A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-21Results posted on the registry: Novartis Pharmaceuticals, secukinumab + secukinumab (NCT04179175)
- 2024-05-22Phase 3 first posted: UCB Biopharma SRL, bimekizumab + ustekinumab (NCT06425549)
- 2024-05-17Results posted on the registry: Beth Israel Deaconess Medical Center, Secukinumab (NCT03791060)
- 2024-05-17Also stopped (terminated): Beth Israel Deaconess Medical Center, Secukinumab (NCT03791060)
- 2024-05-03Phase 3 first posted: Taizhou Mabtech Pharmaceutical Co.,Ltd, CMAB015 + Secukinumab (NCT06398652)
- 2024-04-26Results posted on the registry: Novartis Pharmaceuticals, AIN457 6 mg/kg i.v. + Placebo (NCT04209205)
- 2024-04-19Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Ixekizumab (NCT06374979)
- 2024-03-26Phase 3 first posted: Novartis Pharmaceuticals, Secukinumab (NCT06331312)
- 2024-03-22Results posted on the registry: UCB Biopharma SRL, bimekizumab (NCT05020249)
- 2024-02-29Also stopped (terminated): Novartis Pharmaceuticals, Investigational Arm - secukinumab + Control Arm - placebo (NCT04237116)
- 2024-02-08Results posted on the registry: Novartis Pharmaceuticals, Investigational Arm - secukinumab + Control Arm - placebo (NCT04237116)
- 2024-01-23Results posted on the registry: Novartis Pharmaceuticals, Secukinumab + Placebo (NCT04156620)
- 2023-12-01Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT03347110)
- 2023-11-30Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT04109976)
- 2023-11-01Phase 3 first posted: Livzon Pharmaceutical Group Inc., LZM012 + Secukinumab (NCT06110676)
- 2023-08-25Phase 3 first posted: UCB Biopharma SRL, Bimekizumab (NCT06011733)
- 2023-08-22Results posted on the registry: Novartis Pharmaceuticals, secukinumab 300 mg Q4W + secukinumab 300 mg Q2W (NCT04300296)
- 2023-08-08Results posted on the registry: UCB Biopharma SRL, Bimekizumab (NCT03766685)
- 2023-08-02Results posted on the registry: Novartis Pharmaceuticals, Secukinumab + Placebo (NCT03713632)
- 2023-07-27Results posted on the registry: UCB Biopharma SRL, Bimekizumab + Certolizumab pegol (NCT03215277)
- 2023-06-15Phase 3 first posted: ACELYRIN Inc., Placebo + Izokibep (NCT05905783)
- 2023-04-26Results posted on the registry: Novartis Pharmaceuticals, Secukinumab 300 mg, s.c. + Prednisolone (NCT03765788)
- 2023-03-31Also stopped (withdrawn): Novartis Pharmaceuticals, Secukinumab 300 mg (NCT04488185)
- 2023-03-21Results posted on the registry: AbbVie, Risankizumab (NCT04102007)
- 2023-03-21Results posted on the registry: Eli Lilly and Company, Mirikizumab (NCT03556202)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision